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In designing our study, we faced a tradeoff between analyzing a 
smaller sample with a homogeneous phenotype measure versus 
attaining a larger sample by jointly analyzing data from multiple 
cohorts with heterogeneous measures. For example, in our analysis 
of subjective well-being, we included measures of both life satisfaction 
and positive affect, even though these constructs are conceptually 
distinct7,8. In the Supplementary Note and Supplementary Figure 1, 
we present a theoretical framework for evaluating the costs and 
benefits of pooling heterogeneous measures. In our context, given the 
high genetic correlation across measures, the framework predicts that 
pooling increases statistical power to detect variants. This prediction 
is supported by our results.
RESULTS
GWAS	of	subjective	well-being
Following a prespecified analysis plan, we conducted a sample- 
size-weighted meta-analysis using data from 59 cohorts (n = 298,420 
individuals) of cohort-level GWAS summary statistics. The phenotype 
measure was life satisfaction, positive affect, or (in some cohorts) a 
measure combining life satisfaction and positive affect. We confirmed 
previous findings9 of high pairwise genetic correlation between life 
satisfaction and positive affect using bivariate LD Score regression10 
(ˆ = 0.981 (s.e.m. = 0.065); Supplementary Table 1). Details on the 59 
participating cohorts, their phenotype measures, genotyping, quality 
control filters, and association models are provided in the Online 
Methods, Supplementary Note, and Supplementary Tables 2–6.
As expected under polygenicity11, we observed inflation of the 
median test statistic (λGC = 1.206). The estimated intercept from LD 
Score regression (1.012) suggests that nearly all of the inflation is due 
to polygenic signal rather than bias. We also performed family-based 
analyses that similarly suggested minimal confounding due to 
Very	few	genetic	variants	have	been	associated	with	depression	and	neuroticism,	likely	because	of	limitations	on	sample	size	
in	previous	studies.	Subjective	well-being,	a	phenotype	that	is	genetically	correlated	with	both	of	these	traits,	has	not	yet	been	
studied	with	genome-wide	data.	We	conducted	genome-wide	association	studies	of	three	phenotypes:	subjective	well-being		
(n	=	298,420),	depressive	symptoms	(n	=	161,460),	and	neuroticism	(n	=	170,911).	We	identify	3	variants	associated	with	
subjective	well-being,	2	variants	associated	with	depressive	symptoms,	and	11	variants	associated	with	neuroticism,	including	2	
inversion	polymorphisms.	The	two	loci	associated	with	depressive	symptoms	replicate	in	an	independent	depression	sample.	Joint	
analyses	that	exploit	the	high	genetic	correlations	between	the	phenotypes	(|ˆ	|≈	0.8)	strengthen	the	overall	credibility	of	the	
findings	and	allow	us	to	identify	additional	variants.	Across	our	phenotypes,	loci	regulating	expression	in	central	nervous	system	
and	adrenal	or	pancreas	tissues	are	strongly	enriched	for	association.
Genetic variants associated with subjective well-being, 
depressive symptoms, and neuroticism identified through 
genome-wide analyses
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Subjective well-being—as measured by survey questions on life satis-
faction, positive affect, or happiness—is a major topic of research in 
psychology, economics, and epidemiology. Twin studies have found 
that subjective well-being is genetically correlated with depression 
(characterized by negative affect, anxiety, low energy, bodily aches and 
pains, pessimism, and other symptoms) and neuroticism (a personality 
trait characterized by easily experiencing negative emotions such 
as anxiety and fear)1–3. Depression and neuroticism have received 
much more attention than subjective well-being in genetic association 
studies, but the discovery of genetic variants associated with either of 
them has proven elusive4,5.
Here we report a series of separate and joint analyses of subjective 
well-being, depressive symptoms, and neuroticism, which identify 16 
genome-wide significant associations across the three phenotypes. In 
our two joint analyses, we exploit the high genetic correlation between 
subjective well-being, depressive symptoms, and neuroticism (i) to 
evaluate the credibility of the associations from our initial genome-
wide association study (GWAS) and (ii) to identify new associations 
(beyond those identified by the GWAS). In achieving the first aim, 
we investigate whether SNPs associated with subjective well-being 
‘quasi-replicate’ by testing them for association with depressive symptoms 
and neuroticism. We similarly examine the quasi-replication records 
of the loci associated with depressive symptoms and neuroticism by 
testing them for association with subjective well-being. We find that 
the quasi-replication record closely matches what would be expected, 
given our statistical power, if none of the genome-wide significant 
associations were chance findings. These results strengthen the cred-
ibility of most of the original associations. For our second aim, we use 
a ‘proxy-phenotype’ approach6: we treat the set of loci associated with 
subjective well-being at P < 1 × 10−4 as candidates and test them for 
association with depressive symptoms and neuroticism.
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population stratification (Online Methods). Using a clumping pro-
cedure (Supplementary Note), we identified three approximately 
independent SNPs reaching genome-wide significance (‘lead SNPs’). 
These three lead SNPs are indicated in the Manhattan plot (Fig. 1a) 
and are listed in Table 1. The SNPs had estimated effects in the range 
of 0.015–0.018 s.d. per allele (each R2 ≈ 0.01%).
We also conducted separate meta-analyses of the components of 
our subjective well-being measure—life satisfaction (n = 166,205) and 
positive affect (n = 180,281) (Online Methods). Consistent with our 
theoretical conclusion that pooling heterogeneous measures increases 
power, in our context, the life satisfaction and positive affect analyses 
yielded fewer signals across a range of P-value thresholds than our 
meta-analysis of subjective well-being (Supplementary Table 7).
GWAS	of	depressive	symptoms	and	neuroticism
We conducted auxiliary GWAS of depressive symptoms and neu-
roticism (see the Online Methods, Supplementary Note, and 
Supplementary Tables 8–12 for details on the cohorts, phenotype 
measures, genotyping, association models, and quality control filters). 
For depressive symptoms (n = 180,866), we performed meta-analysis 
on publicly available results from a study performed by the Psychiatric 
Genomics Consortium (PGC)12 together with new results from analy-
ses of the initial release of UK Biobank (UKB) data13 and the Resource 
for Genetic Epidemiology Research on Aging (GERA) cohort (data-
base of Genotypes and Phenotypes (dbGaP), phs000674.v1.p1). In the 
UKB cohort (n = 105,739), we constructed a continuous phenotype 
measure by combining responses to two questions asking about the 
frequency in the past 2 weeks with which the respondent experienced 
feelings of unenthusiasm or disinterest and feelings of depression or 
hopelessness. The other cohorts had ascertained case–control data on 
major depressive disorder (GERA, ncases = 7,231, ncontrols = 49,316; 
PGC, ncases = 9,240, ncontrols = 9,519).
For neuroticism (n = 170,911), we pooled summary statistics from 
a published study by the Genetics of Personality Consortium (GPC)4 
with results from a new analysis of UKB data. GPC (n = 63,661) 
harmonized different neuroticism batteries. In the UKB cohort 
(n = 107,245), our measure was the respondent’s score on a 12-item 
version of the Eysenck Personality Inventory Neuroticism14.
In both the depressive symptoms and neuroticism GWAS, the 
heterogeneous phenotypic measures were highly genetically cor-
related (Supplementary Table 1). As in our subjective well-being 
analyses, there was substantial inflation of the median test statistics 
(λGC = 1.168 for depressive symptoms and 1.317 for neuroticism), 
but the estimated LD Score intercepts (1.008 and 0.998, respectively) 
suggest that bias accounts for little or none of the inflation.
For depressive symptoms, we identified two lead SNPs, indicated 
in the Manhattan plot (Fig. 1b). For neuroticism, our meta-analysis 
yielded 16 loci that were independent according to our locus 
definition (Fig. 1c). However, six of these reside within a well-known 
inversion polymorphism15 on chromosome 8. We established that 
all genome-wide significant signals in the inversion region were 
attributable to the inversion, and we confirmed that the inversion was 
associated with neuroticism in both of our neuroticism data sets, the 
GPC and the UKB (Online Methods and Supplementary Note). In our 
list of lead SNPs (Table 1), we only retain the most strongly associated 
SNP from these six loci to tag the chromosome 8 inversion.
Another lead SNP associated with neuroticism, rs193236081, is 
located within a well-known inversion polymorphism on chromo-
some 17. We established that this association was attributable to the 
inversion polymorphism (Online Methods and Supplementary Note). 
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Figure 1 Manhattan plots of GWAS results. (a–c) Results are shown for subjective well-being (n = 298,420) (a), depressive symptoms (n = 180,866) 
(b), and neuroticism (n = 170,911) (c). The x axis shows chromosomal position, and the y axis shows association significance on a −log10 scale. 
The upper dashed line marks the threshold for genome-wide significance (P = 5 × 10−8), and the lower dashed line marks the threshold for nominal 
significance (P = 1 × 10−5). Each approximately independent genome-wide significant association (lead SNP) is marked by a red ×. Each lead SNP is 
the SNP with the lowest P value within the locus, as defined by our clumping algorithm (supplementary Note).
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Because this inversion yielded only one significant locus and is geneti-
cally complex16, we hereafter simply use its lead SNP as a proxy for it. 
Our neuroticism GWAS therefore identified 11 lead SNPs, 2 of which 
tag inversion polymorphisms. A concurrent neuroticism GWAS using 
a subset of our sample reported similar findings17.
The estimated effects of all lead SNPs associated with depressive 
symptoms and neuroticism were in the range of 0.020–0.031 s.d. per 
allele (R2 ≈ 0.02–0.04%) (Table 1). In the UKB cohort, we estimated 
the effect of an additional allele of the chromosome 8 inversion pol-
ymorphism itself on neuroticism to be 0.035 s.d. (Supplementary 
Table 13). The inversion explains 0.06% of variance in neuroticism 
(roughly the same as the total variance explained jointly by the six 
SNPs in the inversion region).
Genetic	overlap	across	subjective	well-being,	depressive	
symptoms,	and	neuroticism
The three pairwise genetic correlations between our phenotypes, 
estimated using bivariate LD Score regression10, are substantial: 
−0.81 (s.e.m. = 0.046) between subjective well-being and depressive 
symptoms, −0.75 (s.e.m. = 0.034) between subjective well-being and 
neuroticism, and 0.75 (s.e.m. = 0.027) between depressive symptoms 
and neuroticism (Fig. 2a). Using height as a negative control, we also 
examined pairwise genetic correlations between each of our pheno-
types and height and, as expected, found all three to be modest, for 
example, 0.07 with subjective well-being (Supplementary Table 1). 
The high genetic correlations between subjective well-being, depres-
sive symptoms, and neuroticism may suggest that the genetic 
influences on these phenotypes are predominantly related to proc-
esses common across the phenotypes, such as mood, rather than being 
phenotype specific (Fig. 2).
Quasi-replication	and	Bayesian	credibility	analyses
We assessed the credibility of our findings using a standard Bayesian 
framework18,19 in which a positive fraction of SNPs have null 
effects and a positive fraction of SNPs have non-null effects (Online 
Methods). For each phenotype, the non-null effect sizes are assumed 
to be drawn from a normal distribution whose variance is estimated 
from the GWAS summary statistics. As a first analysis, for each lead 
SNP’s association with its phenotype, we calculated the posterior prob-
ability of null association after having observed the GWAS results. 
table 1 summary of polymorphisms identified across analyses 
Genome-wide significant associations
Subjective well-being (n = 298,420)
SNP ID Chr. Position (bp) EA EAF β (s.e.m.) R2 (%) P value n Quasi-replicationd
rs3756290 5 130,951,750 A 0.24 –0.0177 (0.0031) 0.011 9.6 × 10−9 286,851
rs2075677 20 47,701,024 A 0.76 0.0175 (0.0031) 0.011 1.5 × 10−8 288,454 DS**
rs4958581 5 152,187,729 T 0.66 0.0153 (0.0027) 0.011 2.3 × 10−8 294,043 DS***
Neuroticism (n = 170,911)
SNP ID Chr. Position (bp) EA EAF β (s.e.m.) R2 (%) P value n Quasi-replication
rs2572431a 8 11,105,077 T 0.59 0.0283 (0.0035) 0.039 4.2 × 10−16 170,908 SWB*
rs193236081b 17 44,142,332 T 0.77 –0.0284 (0.0043) 0.028 6.3 × 10−11 151,297
rs10960103 9 11,699,270 C 0.77 0.0264 (0.0042) 0.024 2.1 × 10−10 165,380  D23andMe
*
rs4938021 11 113,364,803 T 0.66 0.0233 (0.0037) 0.024 4.0 × 10−10 159,900 D23andMe* , SWB*
rs139237746 11 10,253,183 T 0.51 –0.0204 (0.0034) 0.021 2.6 × 10−9 170,908
rs1557341 18 35,127,427 A 0.34 0.0213 (0.0037) 0.021 5.6 × 10−9 165,579 D23andMe
*
rs12938775 17 2,574,821 A 0.53 –0.0202 (0.0035) 0.020 8.5 × 10−9 163,283 SWB*
rs12961969 18 35,364,098 A 0.2 0.0250 (0.0045) 0.020 2.2 × 10−8 156,758
rs35688236 3 34,582,993 A 0.69 0.0213 (0.0038) 0.019 2.4 × 10−8 161,636
rs2150462 9 23,316,330 C 0.74 –0.0217 (0.0039) 0.018 2.7 × 10−8 170,907
rs12903563 15 78,033,735 T 0.50 0.0198 (0.0036) 0.020 2.9 × 10−8 157,562 D23andMe* ,SWB*
Depressive symptoms (n = 180,866)
SNP ID Chr. Position (bp) EA EAF β (s.e.m.) R2 (%) P value n Quasi-replication/replication
rs7973260 12 118,375,486 A 0.19 0.0306 (0.0051) 0.029 1.8 × 10−9 124,498 D23andMe*
rs62100776 18 50,754,633 A 0.56 –0.0252 (0.0044) 0.031 8.5 × 10−9 105,739 D23andMe* , SWB*
sNPs identified via proxy-phenotype analyses of subjective well-being loci with P < 1 × 10−4
Depressive symptoms in non-overlapping cohorts
SNP ID Chr. Position (bp) EA EAF βDS (SEDS) R2 (%) PDS Bonferroni nDS
rs4346787c 6 27,491,299 A 0.113 –0.023 (0.0059) 0.011 9.8 × 10−5 0.0160 142,265
rs4481363 5 164,483,794 A 0.524 0.014 (0.0038) 0.009 3.1 × 10−4 0.0499 142,265
Neuroticism in non-overlapping cohorts
SNP ID Chr. Position (bp) EA EAF βneuro (SEneuro) R2 (%) Pneuro Bonferroni nneuro
rs10838738 11 47,663,049 A 0.49 0.0178 (0.0039) 0.016 5.0 × 10−6 0.0009 131,864
rs10774909 12 117,674,129 C 0.52 –0.0150 (0.0039) 0.011 1.2 × 10−4 0.0203 131,235
rs6904596 6 27,491,299 A 0.09 –0.0264 (0.0072) 0.012 2.5 × 10−4 0.0423 116,335
rs4481363 5 164,474,719 A 0.49 0.0151 (0.0040) 0.011 1.9 × 10−4 0.0316 122,592
Chr., chromosome; EA, effect allele; EAF, effect allele frequency (all effect sizes are reported in units of s.d. per allele); SWB, subjective well-being; DS, depressive symptoms;  
D, depression; SE, standard error.
aInversion-tagging polymorphism on chromosome 8. bInversion-tagging polymorphism on chromosome 17. cProxy for rs6904596 (r2 = 0.98). dPhenotypes with which a SNP was found to be 
nominally associated in quasi-replication analyses conducted in independent samples: *, significant at the 5% level; **, significant at the 1% level; ***, significant at the 0.1% level.
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We found that, for any assumption about the fraction of non-null 
SNPs in the range 1–99%, the probability of true association always 
exceeded 95% for all 16 loci (and always exceeded 98% for 14 
of them).
To further probe the credibility of the findings, we performed 
quasi-replication exercises (Online Methods) in which we tested 
the subjective well-being lead SNPs for association with depressive 
symptoms and neuroticism. We similarly tested the depressive 
symptoms lead SNPs and the neuroticism lead SNPs for association 
with subjective well-being. Below, we refer to the phenotype for which 
the lead SNP was identified as the first-stage phenotype and the 
phenotype used for the quasi-replication as the second-stage 
phenotype. To avoid sample overlap, for each quasi-replication 
analysis, we omitted any cohorts that contributed to the GWAS of the 
first-stage phenotype.
Results of the quasi-replication of the three subjective well-being 
lead SNPs are shown in Figure 3a. The reference allele for each 
association in the figure is chosen such that the predicted sign of 
the second-stage estimate is positive. We found that two of the 
three subjective well-being lead SNPs were significantly associated 
with depressive symptoms (P = 0.004 and P = 0.001) in the 
predicted direction. For neuroticism, where the second-stage sample 
(n = 68,201) was about one-half as large, the allele increasing subjec-
tive well-being had the predicted sign for all three SNPs, but none 
reached significance.
We also show the results for the depressive symptoms (Fig. 3b) 
and neuroticism (Fig. 3c) lead SNPs. In each panel, the blue crosses 
depict results from the quasi-replications where subjective well-being 
was the second-stage phenotype. We found that the two depressive 
symptoms lead SNPs had the predicted sign for subjective well-
being, and one was nominally significant (P = 0.04). Finally, of the 11 
neuroticism lead SNPs, 9 had the predicted sign for subjective 
well-being. Four of the 11 had nominally significant association with 
subjective well-being, all with the predicted sign. One of the four is 
the SNP tagging the inversion on chromosome 8 (ref. 15). That SNP’s 
association with neuroticism (and likely with subjective well-being) was 
driven by its correlation with the inversion (Supplementary Fig. 2).
To evaluate what these quasi-replication results imply about the 
credibility of the 16 GWAS associations, we compared the observed 
quasi-replication record to the quasi-replication record expected 
given our statistical power. We calculated statistical power using our 
Bayesian framework, under the hypothesis that each lead SNP has a 
non-null effect on both the first- and second-stage phenotypes. Our 
calculations take into account both the imperfect genetic correlation 
between the first- and second-stage phenotypes and inflation of the 
first-stage estimates due to the well-known problem of winner’s curse 
(Online Methods). Of the 19 quasi-replication tests, our calculations 
imply that 16.7 would be expected to yield the anticipated sign and 
6.9 would be significant at the 5% level. The observed numbers were 
16 and 7. Our quasi-replication results are thus consistent with the 
hypothesis that none of the 16 genome-wide significant associations 
are chance findings and in fact strengthen the credibility of our GWAS 
results (Supplementary Table 14).
Lookup	of	depressive	symptoms	and	neuroticism	lead	SNPs
Investigators of an ongoing large-scale GWAS of major depressive disor-
der (n = 368,890) in the 23andMe cohort shared association results for 
the loci identified in our depressive symptoms and neuroticism analy-
ses (Online Methods and Supplementary Table 15; C.L. Hyde, M.W. 
Nagle, C. Tian, X. Chen, S.A. Paciga et al., unpublished data). Because the 
depression sample overlaps with our subjective well-being sample, we did 
not request a lookup of the SNPs associated with subjective well-being.
In Figure 3b,c, the results are depicted as green crosses. For 
interpretational ease, we chose the reference allele so that positive 
coefficients imply that the estimated effect is in the predicted 
direction. All 13 associations had the predicted sign. Of the 11 neurot-
icism polymorphisms, 4 were significantly associated with depression 
at the 5% level. Both of the depressive symptoms lead SNPs replicated 
(P = 0.004 and P = 0.015), with effect sizes (0.007 and −0.007 s.d. per 
allele) close to those predicted by our Bayesian framework (0.008 and 
−0.006) (Supplementary Tables 14 and 15).
The top part of Table 1 summarizes the results for the 16 lead 
SNPs identified across our separate genome-wide association analyses 
of the three phenotypes. The rightmost column summarizes the 
statistical significance of the quasi-replication and depression lookup 
analyses of each SNP.
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Figure 2 Genetic correlations. Correlations were estimated using  
bivariate LD Score (LDSC) regression. (a) Genetic correlations  
between subjective well-being, depressive symptoms, and neuroticism  
(‘our three phenotypes’), as well as between our three phenotypes and  
height. (b) Genetic correlations between our three phenotypes and  
selected neuropsychiatric phenotypes. (c) Genetic correlations  
between our three phenotypes and selected physical health  
phenotypes. In b and c, we report the negative of the estimated  
correlation with depressive symptoms and neuroticism (but not subjective  
well-being). Error bars represent 95% confidence intervals.
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Proxy-phenotype	analyses
To identify additional SNPs associated with depressive symptoms, we 
conducted a two-stage ‘proxy-phenotype’ analysis (Online Methods). 
In the first stage, we ran a new GWAS of subjective well-being to 
identify a set of candidate SNPs. Specifically, from each locus 
exhibiting suggestive evidence of association (P < 1 × 10−4) with 
subjective well-being, we retained the SNP with the lowest P value 
as a candidate. In the second stage, we tested these candidates for 
association with depressive symptoms at the 5% significance 
threshold, Bonferroni adjusted for the number of candidates. We used 
an analogous two-stage procedure to identify additional SNPs 
associated with neuroticism. The first-stage subjective well-being 
sample differed across the two proxy-phenotype analyses (and from 
the primary subjective well-being GWAS sample) because we assigned 
cohorts across the first and second stages so as to maximize statistical 
power for the overall procedure.
For depressive symptoms, there were 163 candidate SNPs. 
Of these, 115 (71%) had the predicted direction of effect on depressive 
symptoms, 20 were significantly associated at the 5% significance level (19 
in the predicted direction), and 2 remained significant after Bonferroni 
adjustment. For neuroticism, there were 170 candidate SNPs. Of these, 
129 (76%) had the predicted direction of effect, all 28 SNPs significant at 
the 5% level had the predicted sign, and 4 of these remained significant 
after Bonferroni adjustment (Supplementary Fig. 3 and Supplementary 
Tables 16 and 17). Two of the four were SNPs also identified in the 
proxy-phenotype analysis for depressive symptoms.
The four SNPs in total identified by the proxy-phenotype analyses 
are listed in Table 1.
Biological	analyses
To shed some light on possible biological mechanisms underlying our 
findings, we conducted several analyses.
We began by using bivariate LD Score regression10 to quantify the 
amount of genetic overlap between each of our three phenotypes and 
ten neuropsychiatric and physical health phenotypes. The estimates 
for subjective well-being and the negative of the estimates for depres-
sive symptoms and neuroticism (as subjective well-being is negatively 
genetically correlated with depressive symptoms and neuroticism) are 
shown in Figure 2b,c. Subjective well-being, depressive symptoms, 
and neuroticism had strikingly similar patterns of pairwise genetic 
correlation with the other phenotypes.
We examined five neuropsychiatric phenotypes: Alzheimer disease, 
anxiety disorders, autism spectrum disorder, bipolar disorder, and 
schizophrenia (Fig. 2b). For four of these phenotypes, genetic correla-
tions with depression (but not neuroticism or subjective well-being) 
were reported in Bulik-Sullivan et al.10. For schizophrenia and bipolar 
disorder, our estimated correlations with depressive symptoms, 0.33 
and 0.26, are substantially lower than the point estimates of Bulik-
Sullivan et al. but are contained within their 95% confidence intervals. 
By far, the largest genetic correlations we estimated were with 
anxiety disorders: −0.73 with subjective well-being, 0.88 with depres-
sive symptoms, and 0.86 with neuroticism. To our knowledge, genetic 
correlations estimated from GWAS data have not previously been 
reported for anxiety disorders.
We also examined five physical health phenotypes that are known 
or believed to be risk factors for various adverse health outcomes: 
body mass index (BMI), ever-smoker status, coronary artery disease, 
fasting glucose levels, and triglyceride levels (Fig. 2c). The estimated 
genetic correlations were all small in magnitude, consistent with 
earlier work, although the greater precision of our estimates allowed 
us to reject null effects in most cases. The signs were generally 
consistent with those of the phenotypic correlations reported in ear-
lier work between our phenotypes and outcomes such as obesity20, 
smoking21,22, and cardiovascular health23.
Next, to investigate whether our GWAS results are enriched in partic-
ular functional categories, we applied stratified LD Score regression24 
to our meta-analysis results. In our first analysis, we report estimates 
for all 53 functional categories included in the ‘baseline model’; 
the results for subjective well-being, depressive symptoms, and 
neuroticism were broadly similar (Supplementary Tables 18–20) 
and are in line with what has been found for other phenotypes24. In 
our second analysis, the categories were groupings of SNPs likely to 
regulate gene expression in cells of a specific tissue. The estimates for 
subjective well-being, depressive symptoms, and neuroticism are simi-
lar to each other and different from those for height, which was again 
included as a benchmark25 (Fig. 4a and Supplementary Table 21).
We found significant enrichment of central nervous system for 
all three phenotypes and, perhaps more surprisingly, enrichment of 
adrenal/pancreas for subjective well-being and depressive symptoms. 
The cause of the adrenal/pancreas enrichment is unclear, but we note 
that the adrenal glands produce several hormones, including cortisol, 
epinephrine, and norepinephrine, known to have important roles in 
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the bodily regulation of mood and stress. It has been robustly found 
that blood serum levels of cortisol in patients afflicted by depression 
are elevated relative to those in controls26.
Whereas the above analyses use genome-wide data, we also con-
ducted three analyses (Online Methods) restricted to the 16 GWAS 
and 4 proxy-phenotype SNPs in Table 1. In brief, we ascertained 
whether each SNP (or a variant in strong linkage disequilibrium 
(LD) with it) fell into any of the following three classes: (i) resides in 
a locus for which genome-wide significant associations with other 
phenotypes have been reported (Supplementary Table 22), (ii) is 
nonsynonymous (Supplementary Table 23), and (iii) is an expres-
sion quantitative trait locus (eQTL) in blood or in 1 of 14 other 
tissues (although the non-blood analyses are based on smaller samples) 
(Supplementary Table 24). Here we highlight a few particularly 
interesting results.
We found that 5 of the 20 SNPs are in loci in which genome-
wide significant associations have previously been reported. Two of 
these five are loci associated with schizophrenia. Interestingly, one 
of them harbors the gene DRD2, which encodes the D2 subtype of 
the dopamine receptor, a target for antipsychotic drugs27 that is also 
known to have a key role in neural reward pathways28. Motivated 
by these findings, as well as by the modest genetic correlations with 
schizophrenia (Fig. 2b), we examined whether the SNPs identified 
in a recent study of schizophrenia29 are enriched for association with 
neuroticism in our non-overlapping UKB sample (n = 107,245). We 
conducted several tests and found strong evidence of such enrichment 
(Supplementary Note). For example, we found that the P values of 
the schizophrenia-associated SNPs tended to be much lower than the 
P values of a randomly selected set of SNPs matched on allele fre-
quency (P = 6.50 × 10−71).
Perhaps the most notable pattern that emerged from our biological 
analyses is that the inversions on chromosomes 8 and 17 were impli-
cated consistently across all analyses. The inversion-tagging SNP on 
chromosome 8 is in LD with SNPs that have previously been found 
to be associated with BMI30 and triglyceride levels31 (Supplementary 
Table 22). We also conducted eQTL analyses in blood for the inversion 
itself and found that it is a significant cis-eQTL for seven genes 
(Supplementary Table 24). All seven genes are positioned in close 
proximity to the inversion breakpoints (Fig. 4b), suggesting that the 
molecular mechanism underlying the inversion’s effect on neuroti-
cism could involve the relocation of regulatory sequences. Two of 
the genes (MSRA and MTMR9) are known to be highly expressed 
in tissues and cell types that belong to the nervous system, and two 
(BLK and MFHAS1) are known to be highly expressed in the immune 
system. In the tissue-specific analyses, we found that the SNP tagging 
the inversion is a significant eQTL for two genes, AF131215.9 (in tibial 
nerve and thyroid tissue analyses) and NEIL2 (in tibial nerve tissue), 
both of which are also located near the inversion breakpoint.
The SNP tagging the chromosome 17 inversion is a significant cis-
eQTL for five genes in blood and is an eQTL in all 14 other tissues 
(Supplementary Table 24). It alone accounts for 151 of the 169 
significant associations identified in the 14 tissue-specific analyses. 
Additionally, the SNP is in near-perfect LD (r2 > 0.97) with 11 
missense variants (Supplementary Table 23) in three different genes, 
one of which is MAPT. MAPT, which is also implicated in both blood 
and other tissue-specific analyses, encodes a protein important in the 
stabilization of microtubules in neurons. Associations have previously 
been reported between SNPs in MAPT (all of which are in strong LD 
with our inversion-tagging SNP) and neurodegenerative disorders, 
including Parkinson disease32 and progressive supranuclear palsy33, 
a rare disease whose symptoms include depression and apathy.
DISCUSSION
The discovery of genetic loci associated with subjective well-being, 
depression, and neuroticism has proven elusive. Our study identified 
several credible associations for two main reasons. First, our analyses 
had greater statistical power than previous studies because ours were 
conducted in larger samples. Our GWAS findings—3 loci associated 
with subjective well-being, 2 loci associated with depressive 
symptoms, and 11 loci associated with neuroticism—support the 
view that GWAS can successfully identify genetic associations 
with highly polygenic phenotypes in sufficiently large samples5,34. 
A striking finding is that two of our identified associations are with 
inversion polymorphisms.
Second, our proxy-phenotype analyses further boosted power by 
exploiting the strong genetic overlap between our three phenotypes. 
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These analyses identified two additional loci associated with 
neuroticism and two additional loci associated with both depressive 
symptoms and neuroticism. Through our quasi-replication tests, 
we also demonstrated how studying genetically overlapping pheno-
types in concert can provide evidence on the credibility of GWAS 
findings. Our direct replication of the two genome-wide significant 
associations with depressive symptoms in an independent depression 
sample provides further confirmation of these findings (Fig. 2b and 
Supplementary Table 15).
We were able to assemble much larger samples than previous work 
in part because we combined data across heterogeneous phenotype 
measures. Our results reinforce the conclusions from our theoretical 
analysis that doing so increases statistical power, but our strategy also 
has drawbacks. One is that mixing different measures may make any 
discovered associations more difficult to interpret. Research studying 
higher-quality measures of the various facets of subjective well-being, 
depressive symptoms, and neuroticism is a critical next step. Our 
results can help facilitate such work because, if the variants we identify 
are used as candidates, studies conducted in the smaller samples in 
which more fine-grained phenotype measures are available can be 
well powered.
Another limitation of mixing different measures is that doing so 
may reduce the heritability of the resulting phenotype, if the measures 
are influenced by different genetic factors. Indeed, our estimates of 
SNP-based heritability10 for our three phenotypes are quite low: 0.040 
(s.e.m. = 0.002) for subjective well-being, 0.047 (s.e.m. = 0.004) for 
depressive symptoms, and 0.091 (s.e.m. = 0.007) for neuroticism. 
We correspondingly find that polygenic scores constructed from all 
measured SNPs explain a low fraction of variance in independent 
samples: ~0.9% for subjective well-being, ~0.5% for depressive 
symptoms, and ~0.7% for neuroticism (Online Methods). The low 
heritabilities imply that, even when polygenic scores can be estimated 
using much larger samples than ours, they are unlikely to attain 
enough predictive power to be clinically useful.
According to our Bayesian calculations, the true explanatory power 
(corrected for winner’s curse) of the SNP with the largest posterior R2 
is 0.003% for subjective well-being, 0.002% for depressive symptoms, 
and 0.011% for neuroticism (Supplementary Table 14). These effect 
sizes imply that, to account for even a moderate share of heritability, 
hundreds or (more likely) thousands of variants will be required. 
They also imply that our study’s power to detect variants of these 
effect sizes was not high—for example, our statistical power to detect 
the lead SNP with the largest posterior R2 value was only ~13%—
which in turn means it is likely that there exist many variants with 
effect sizes comparable to those for our identified SNPs that evaded 
detection. These estimates suggest that many more loci will be found 
in studies with sample sizes realistically attainable in the near future. 
Consistent with this projection, when we perform meta-analysis on 
the 54 SNPs reaching P < 1 × 10−5 in our analyses of depressive symp-
toms together with the 23andMe replication sample for depression, 
the number of genome-wide significant associations increases from 
two to five (Supplementary Table 15).
URLs. Genotype-Tissue Expression Portal, http://www.GTExportal.
org/; Social Science Genetic Association Consortium (SSGAC), 
http://www.thessgac.org/#!data/kuzq8.
METhODS
Methods and any associated references are available in the online 
version of the paper.
Accession codes. For neuroticism and depressive symptoms, we pro-
vide meta-analysis results from the combined analyses for all variants. 
For subjective well-being, meta-analysis results for all variants are 
provided for the full sample excluding 23andMe, for which only 
up to 10,000 SNPs can be reported. Therefore, for the subjective 
well-being meta-analysis, we provide results for 10,000 SNPs. 
Meta-analysis results can be downloaded from the SSGAC website.
Note: Any Supplementary Information and Source Data files are available in the 
online version of the paper.
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GWAS of subjective well-being. Genome-wide association analyses were per-
formed at the cohort level according to a prespecified analysis plan. Genotyping 
was performed using a range of common, commercially available genotyping 
arrays. The analysis plan instructed cohorts to upload results imputed using 
the HapMap 2 CEU (r22.b36) reference sample35. We performed meta-analysis 
on summary association statistics from 59 contributing cohorts with a com-
bined sample size of 298,420 individuals. Before meta-analysis, a uniform 
set of quality control procedures were applied to the cohort-level summary 
statistics, including but not limited to the EasyQC36 protocol. All analyses 
were restricted to European-ancestry individuals.
We performed a sample-size-weighted meta-analysis of the cohort-level 
summary statistics. To adjust standard errors for non-independence, we 
inflated them using the square root of the estimated intercept from an LD 
Score regression10. We also performed secondary, separate meta-analyses of 
positive affect (n = 180,281) and life satisfaction (n = 166,205) and a post hoc 
genome-wide analysis of subjective well-being in cohorts with 1000 Genomes 
Project–imputed data (n = 229,883) (Supplementary Figs. 4–6).
Detailed cohort descriptions, information about cohort-level genotyping 
and imputation procedures, cohort-level measures, and quality control fil-
ters are shown in Supplementary Tables 2–6. Association results from the 
following four meta-analyses are reported: the primary subjective well-being 
analysis, the life satisfaction analysis, the positive affect analysis, and the 
post hoc subjective well-being analysis (Supplementary Table 7). For each 
phenotype, we provide association results for the set of approximately 
independent SNPs that attained a P value smaller than 1 × 10−5. We identify 
these SNP using the same clumping algorithm as for the lead SNPs but with the 
P-value threshold set at 1 × 10−5 instead of genome-wide significance.
GWAS of depressive symptoms and neuroticism. Our auxiliary genome-wide 
association studies of depressive symptoms and neuroticism were conducted 
in 1000 Genomes Project–imputed data, combining new genome-wide asso-
ciation analyses with publicly available summary statistics from previously 
published studies. We applied a similar quality control protocol to that used 
in our primary subjective well-being analysis. In the depressive symptoms 
meta-analysis (n = 180,866), we weighted the UKB analysis by sample size and 
the two case–control studies by effective sample size. In the neuroticism meta-
analysis (n = 170,911), we performed a sample-size-weighted fixed-effects 
meta-analysis of the UKB data and the publicly available summary statistics 
from a previous GWAS of neuroticism.
Detailed cohort descriptions, information about cohort-level genotyping 
and imputation procedures, and quality control filters are provided in 
Supplementary Tables 8–12. Quantile–quantile plots of the neuroticism and 
depressive symptoms meta-analysis results are shown in Supplementary Figure 7. 
Association results for the set of approximately independent SNPs that attained 
a P value smaller than 1 × 10−5 are supplied in Supplementary Table 25.
Population stratification. To quantify the fraction of the observed inflation 
of the mean test statistic that is due to bias, we used LD Score regression10. 
The estimated LD Score regression intercepts were all close to 1, suggesting no 
appreciable inflation of the test statistics attributable to population stratification 
in any of our subjective well-being, depressive symptoms or neuroticism 
meta-analyses (Supplementary Fig. 8). For all three phenotypes, our estimates 
suggest that less than 2% of the observed inflation of the mean test statistic 
was accounted for by bias.
In our primary GWAS of subjective well-being, we also used two family-
based analyses to test for and quantify stratification biases. These analyses used 
within-family estimates, the coefficients from regressing the difference in phe-
notype across siblings on the difference in siblings’ genotype (and controls). 
These within-family estimates are not biased by population stratification 
because siblings share their ancestry entirely, and therefore differences in 
siblings’ genotypes cannot be due to the siblings being from different 
population groups. We performed meta-analysis on association statistics from 
within-family analyses conducted in four cohorts.
In the first analysis, we estimated the fraction of SNPs for which the signs 
of the within-family estimates were concordant with the signs of the estimates 
obtained from a GWAS identical to our primary subjective well-being GWAS 
except with the four family cohorts excluded. For the 112,884 approximately 
independent SNPs considered, we found a sign concordance of 50.83%, which 
is significantly greater than 50% (P = 1.04 × 10−8). Under the null hypothesis 
of no population stratification, the observed sign concordance nearly per-
fectly matches the expected rate after adjustment for winner’s curse at 50.83% 
(Supplementary Fig. 9).
The second analysis used the within-family regression coefficient estimates 
(that is, not only their signs) to estimate the amount of stratification bias. 
For each SNP j, let bˆ j  denote the GWAS estimate and let bˆWF,j  denote the 
within-family estimate. Under the assumption that the causal effect of each 
SNP is the same within families as in the population, we can decompose the 
estimates as 
ˆ
ˆ
,
b b
b b
j j j j
j j j
s U
V
= + +
= +WF
where βj is the true underlying GWAS parameter for SNP j, sj is the bias due 
to stratification (defined to be orthogonal to βj and Uj), and Uj and Vj are the 
sampling variances of the estimates with E(Uj) = E(Vj) = 0. Whenever sj ≠ 0, 
the GWAS estimate of bˆ j  is biased away from the population parameter βj. 
The proportion of variance in the GWAS coefficients accounted for by true 
genetic signals can be written as 
var
var var
b
b
j
j js
( )
( )+ ( )  
In the Supplementary Note, we show that, with estimates bˆ j and ˆ ,bWF j  (and 
their standard errors) from independent samples, it is possible to consistently 
estimate the above ratio. The 95% confidence interval for the ratio implies that 
between 72% and 100% of the signal in the GWAS estimates is a result of true 
genetic effects on subjective well-being rather than stratification.
Analyses of inversion polymorphisms. Two genome-wide significant SNPs 
for the neuroticism analysis are located within well-known inversion polymor-
phisms, on chromosomes 8 and 17. Using the genotypic data available for UKB 
participants, we called the inversion genotypes for UKB participants using a 
principal-components analysis (PCA)–mixture method. For both inversions, 
the method clearly distinguishes three clusters of genotypes, corresponding to 
inversion genotypes (Supplementary Fig. 10). We validated the PCA–mixture 
procedure using existing methods designed to call inversion genotypes37 
(Supplementary Table 26).
For each inversion, we established that the inversion-tagging SNPs were 
always located in close proximity to the inversion region (Fig. 3b and 
Supplementary Figs. 10 and 11). We list the 20 variants that most strongly 
correlate with the principal components that capture the inversion polymor-
phisms on chromosomes 8 (Supplementary Table 27) and 17 (Supplementary 
Table 28). In additional analyses, we confirmed that the inversion is asso-
ciated with neuroticism and subjective well-being in independent cohorts 
(Supplementary Figs. 12 and 13 and Supplementary Tables 29 and 30).
Proxy-phenotype analyses. In these analyses, we used a two-stage approach 
that has been successfully applied in other contexts6. In the first stage, we 
conducted a meta-analysis of our first-stage proxy phenotype and used our 
clumping procedure to identify the set of approximately independent SNPs at 
the P-value threshold of 1 × 10−4. In the second stage, we tested SNPs identified 
in stage 1 (or high-LD proxies for them) for association with a second-stage 
phenotype in an independent (non-overlapping) sample. In our analyses, we 
used our primary phenotype of subjective well-being as the proxy phenotype. 
We conducted one analysis with depressive symptoms as the second-stage 
phenotype and one analysis with neuroticism as the second-stage phenotype. 
In the analyses, we omitted cohorts from the first or second stage as needed 
to ensure that the samples in the two stages were non-overlapping. The cohort 
restrictions imposed are listed in Supplementary Table 31. These cohort 
restrictions, as well as the P-value threshold of 1 × 10−4, were chosen before 
the data were analyzed on the basis of statistical power calculations.
To test for cross-phenotype enrichment, we used a non-parametric pro-
cedure that tests whether lead SNPs are more strongly associated with the 
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second-stage phenotype than randomly chosen sets of SNPs with a similar 
distribution of allele frequencies (Supplementary Note).
To test the individual lead SNPs for experiment-wide significance, we 
examined whether any of the lead SNPs (or their high-LD proxies) were signif-
icantly associated with the second-stage phenotype at the Bonferroni-adjusted 
significance level of 0.05/number of SNPs tested.
Genetic correlations. We used bivariate LD Score regression10 to quantify the 
amount of genetic heterogeneity among the phenotypic measures pooled in 
each of our three separate meta-analyses. For subjective well-being, we esti-
mated a pairwise correlation of 0.981 (s.e.m. = 0.065) between life satisfaction 
and positive affect, 0.897 (s.e.m. = 0.017) between well-being (our measure 
that combines life satisfaction and positive affect) and life satisfaction, and 
1.031 (s.e.m. = 0.019) between positive affect and well-being. For depres-
sive symptoms, we estimated a genetic correlation of 0.588 (s.e.m. = 0.242) 
between GERA and PGC, 0.972 (s.e.m. = 0.216) between GERA and UKB, and 
0.797 (s.e.m. = 0.108) between UKB and PGC. Finally, we estimated a genetic 
correlation of 1.11 (s.e.m. = 0.14) between the measures of neuroticism in 
the UKB analyses and the summary statistics from a previously published 
meta-analysis4.
Bayesian credibility analyses. To evaluate the credibility of our findings, we 
use a standard Bayesian framework18 in which our prior distribution for any 
SNP’s effect is 
b t p∼ N j( , )0
0
2 with probability
otherwise



  
Here π is the fraction of non-null SNPs and t j2 is the variance of the non-null 
SNPs for trait j ∈ {subjective well-being, depressive symptoms, neuroticism}. 
In this framework, credibility is defined as the probability that a given SNP 
is non-null.
We begin with univariate analyses of the GWAS results that do not incor-
porate the additional information from the quasi-replication analyses of the 
16 lead SNPs reported in Table 1. We use the three subjective well-being- 
associated SNPs to illustrate our approach, but we use analogous procedures 
when analyzing depressive symptoms and neuroticism. We calculate cred-
ibility for each value π ∈ {0.01, 0.02, …, 0.99}. For each assumed value of π, 
we estimate tSWB2  by maximum likelihood (Supplementary Note). For each 
SNP, we use Bayes’ rule to obtain a posterior estimate of credibility for each of 
the assumed values of π. For all considered values of π and all three SNPs, the 
posterior probability that the SNP is null is below 1% (Supplementary Fig. 14). 
Similar analyses of the depressive symptoms and neuroticism SNPs show that 
the posterior probability never exceeds 5%.
In our joint analyses, we consider two phenotypes with genetic correla-
tion rg. We make the simplifying assumption that the set of null SNPs is the 
same for both phenotypes. The joint distribution of a SNP’s effect on the two 
phenotypes is then given by 
b
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With coefficient estimates, bˆ1  and bˆ2 , obtained from non-overlapping 
samples, the variance–covariance matrix of the estimation error will be 
diagonal. We denote the diagonal entries of this matrix, which represent 
the variances of the estimation error in the two samples, by s12  and s22 . 
This gives us the joint prior distribution
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To select parameter values for the prior, we use the estimates of rg reported 
in Supplementary Table 1, and we estimate the parameters π, t12, and t22 
from GWAS summary statistics using a maximum-likelihood procedure. 
For this procedure, we make the standard assumption10,38 that the variance 
in a SNP’s effect size is inversely proportional to the variance of its genotype, 
2 × MAF × (1 – MAF), where MAF is the minor allele frequency.
The credibility estimates follow from applying Bayes’ rule to calculate 
either the probability that the SNP is non-null (an event denoted C) given 
only the first-stage estimate, ˆ | ˆb bP C 1( ) , or the probability that the SNP is non-
null conditional on the results of both the first-stage GWAS and the quasi- 
replication analysis, ˆ | ˆ , ˆb b bP C 1 2( ). Credibility estimates for our lead SNPs are 
in Supplementary Table 14.
To calculate the expected record of a replication or quasi-replication study, 
we assume that the SNP is non-null for both phenotypes. (This is analogous 
to a standard power calculation for a single phenotype, in which the SNP 
is assumed to be non-null.) Under this assumption, bˆ1 and bˆ2  are jointly 
normally distributed, implying that the conditional distribution of bˆ2 given 
bˆ1 is 
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Using this equation, we can calculate the probability that the GWAS esti-
mates will have concordant signs across the two phenotypes, or that the GWAS 
estimate of the second-stage phenotype will reach some level of significance. 
These probabilities can be summed over the set of lead SNPs to generate the 
expected number of SNPs meeting the criterion.
To obtain effect size estimates for a SNP that are adjusted for winner’s curse 
(Supplementary Table 32), we use the mean of the posterior distribution 
of the SNP’s effect, conditional on the quasi-replication result and the SNP 
being non-null. We derive the posterior distribution and expected R2 in the 
Supplementary Note.
Lookup of SNPs associated with depressive symptoms and neuroticism in 
an independent depression study. We partnered with the investigators of 
an ongoing large-scale GWAS of major depressive symptoms (n = 368,890) 
to follow up on the associations identified in the depressive symptoms and 
neuroticism analyses. The participants of the study were all European-ancestry 
customers of 23andMe, a personal genomics company, who responded to 
online survey questions about mental health. We did not request results for 
the SNPs identified in the subjective well-being or proxy-phenotype analyses 
because these were both conducted in samples that overlap with the 23andMe’s 
depression sample. For details on association models, quality control filters, 
and the ascertainment of depression status, we refer to the companion study 
(C.L. Hyde, M.W. Nagle, C. Tian, X. Chen, S.A. Paciga et al. unpublished data). 
The P values we report are based on standard errors that have been adjusted 
using the intercept from an LD Score regression10.
Polygenic prediction. To evaluate the predictive power of a polygenic score 
derived from the subjective well-being meta-analysis results, we used two 
independent withheld cohorts: the Health and Retirement Study (HRS)39 
and the Netherlands Twin Register (NTR)40,41. To generate the weights for 
the polygenic score, we performed meta-analyses of the pooled subjective 
well-being phenotype excluding each of the withheld cohorts, applying a 
minimum-sample-size filter of 100,000 individuals (Supplementary Note). 
The results from these analyses are reported in Supplementary Table 33 and 
depicted in Supplementary Figure 15.
Biological annotation. For biological annotation of the 20 SNPs in Table 1, 
we generated a list of LD partners for each of the original SNPs. A SNP was 
considered to be an LD partner for the original SNP if (i) its pairwise LD with 
the original SNP exceeded r2 = 0.6 and (ii) it was located within 250 kb of the 
original SNP. We also generated a list of genes residing within loci tagged by 
our lead SNPs (Supplementary Table 34).
We used the NHGRI GWAS catalog42 to determine which of our 20 SNPs 
(and their LD partners) were in LD with SNPs for which genome-wide 
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significant associations have previously been reported. Because the GWAS 
catalog does not always include the most recent GWAS results available, 
we included additional recent GWAS studies. We used the tool HaploReg43  
to identify nonsynonymous variants in LD with any of the 20 SNPs or their 
LD partners.
We examined whether the 20 polymorphisms in Table 1 were associated 
with gene expression levels (Supplementary Table 24 and Supplementary 
Note). The cis-eQTL associations were performed in 4,896 peripheral blood 
gene expression and genome-wide SNP samples from two Dutch cohorts 
measured on the Affymetrix U219 platform40,41,44. We also performed eQTL 
lookups of our 20 SNPs in the Genotype-Tissue Expression Portal45,46. We 
restricted the search to the following trait-relevant tissues: hippocampus, 
hypothalamus, anterior cingulate cortex (BA24), putamen (basal ganglia), 
frontal cortex (BA9), nucleus accumbens (basal ganglia), caudate (basal gan-
glia), cortex, cerebellar hemisphere, cerebellum, tibial nerve, thyroid, adrenal 
gland, and pituitary.
Finally, using a gene coexpression database47, we explored the predicted func-
tions of genes colocating with the 20 SNPs in Table 1 (Supplementary Table 35).
Further details appear in a Supplementary Note.
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